Abstract
Comparison of Risk Factors for Trastuzumab-Related Cardiotoxicity in Elderly and Non-Elderly Breast Cancer Patients
Highlights
Epidermal growth factor receptor 2 (HER2) is expressed in approximately 25% of all breast cancers [1]
The baseline left ventricular ejection fraction (LVEF) was significantly related to cardiotoxicity both in elderly and non-elderly patients
The baseline LVEF value of less than 67% and 66% in elderly patients and non-elderly patients respectively was a significant predictive factor of trastuzumab-related cardiotoxicity
Summary
Epidermal growth factor receptor 2 (HER2) is expressed in approximately 25% of all breast cancers [1]. Trastuzumabbased chemotherapy significantly improves the prognostic outcomes of patients with early stage and metastatic HER2positive breast cancer [2,3]. Previous reports of large-scaled clinical trials have suggested that older age and cardiac comorbidity are important risk factors associated with cardiotoxity among trastuzumab-treated patients [6,7]. Trastuzumab-based chemotherapy is preferentially avoided for elderly patients in consideration of the risk of cardiotoxicity, while some can safely receive the treatment with trastuzumab. A few studies have suggested that some clinical factors such as history of cardiac disease, diabetes, hypertension, and obesity are associated with trastuzumab-related cardiotoxicity [8,9], but the potential risk factor in elderly patients warrant further investigations. Trastuzumab-based treatment benefits patients with HER2-positive early and metastatic breast cancer improving both disease free and overall survival, cardiotoxicity has been a crucial issue. The purpose of this study is to investigate predictive risk factors for trastuzumab-related cardiotoxicity in elderly and non-elderly patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
